Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Video library· Dr. William WallaceAudio: English

Targeting Longevity: NMN vs. NR for NAD+ Restoration

Thumbnail from YouTube. Playing loads the YouTube player.

History & recommendationsOff

Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.

Up to 120 items · 90 days. Turning this off deletes the history.
Open saved items & history →

About this video

Creator description · original textText language: English

In this episode of Daily Value, we look at science of Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR), two NAD+ precursors gaining traction in longevity research. Both supplements aim to restore NAD+ levels, critical for energy metabolism and cellular repair, yet their distinct pathways and tissue-specific effects suggest considerations for choosing one over the other. https://pubmed.ncbi.nlm.nih.gov/38645109/ https://iadns.onlinelibrary.wiley.com/doi/10.1002/fft2.511 0:00 – Introduction 0:43 – What is NAD+ and why it matters 1:30 – How NMN and NR differ mechanistically 2:57 – The 2024 study: methods & design 5:26 – Choosing between NMN and NR 7:58 – Summary & closing thoughts https://www.instagram.com/dr.williamwallace/ https://www.facebook.com/williamwallacePhD https://twitter.com/williamwallace https://www.linkedin.com/in/drwilliamwallace/

Dr. William Wallace · 9 min · Source published: 2025-01-06

Added to Harbor: 10/23/2026

Original on YouTube ↗

Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…